Citations

Clear

626 citation(s) found for "Mehta, SH".

Activation of the Classical Complement Pathway by Fc Fragment of Human IgA
Burritt, Mary F., Calvanico, Nickolas J., Mehta, Satish , Tomasi, Thomas B.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 118 | Issue: 2 | Pages: 723-725

10.4049/jimmunol.118.2.723 Get It

Summary Intact Fcα fragments from five human IgA myeloma proteins were produced by two different methods, high temperature trypsinolysis and IgA protease digestion. Three of the Fcα fragments activated the classical pathway as determined by the titers of the individual complement components. Two other fragments did not fix complement by either pathway.
Effect of Caffeine on Colonic Manometry in Children
Mehta, Vijay, Hopson, Puanani , Irastorza, Laura, Rizvi, Syed Ahsan, Fernandez, Jenelle , Thomas, Jessina, Nabar, Shruti , Safder, Shaista , Rizvi, Syed Ahsan

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | December 27, 2022 | Volume: 76 | Issue: 1 | Pages: 20-24

10.1097/mpg.0000000000003627 | PMID 36574000 Get It

Objectives:Coffee and caffeinated products have been widely consumed for many centuries. Previous adult studies have suggested that both coffee and decaffeinated beverages induce colonic motility. However, no study has been conducted in pediatrics, and the role of caffeine alone in pediatric colonic motility needs to be explored.Methods:A prospective study of pediatric patients undergoing standard colonic motility testing that were able to consume caffeinated coffee, decaffeinated coffee, and caffeine tablet during colonic manometry. Patients who had a gastrocolonic reflex and high amplitude propagated contractions (HAPCs) in response to intraluminal administration of bisacodyl in the colon were included in the final analyses.Results:Thirty‐eight patients were recruited, 22 of which were excluded, 11 due to abnormal studies (no HAPC seen in response to intraluminal response to bisacodyl), and 11 due to inability to consume all study agents or complete the study. Sixteen patients met criteria for final analyses. Intracolonic bisacodyl produced a larger area under the curve (AUC) compared to all other agents. Caffeinated coffee resulted in a higher AUC, motility index (MI), and time to HAPC compared with decaffeinated coffee (P < 0.05). There was no significant difference between caffeinated coffee and caffeine tablet, or caffeine tablet and decaffeinated coffee.Conclusions:Caffeine is indeed a colonic stimulant; however, other components of caffeinated and non‐caffeinated beverages likely induce colonic response and require further evaluation for possible use as a colonic stimulant.
Artificial intelligence–augmented electrocardiography for left ventricular systolic dysfunction in patients undergoing high-sensitivity cardiac troponin T
Knott, Jonathan D , Attia, Zachi I. , Ola, Olatunde , Mehta, Ramila A. , Akula, Ashok , Hodge, David O. , Gulati, Rajiv , Friedman, Paul A. , Jaffe, Allan S. , Sandoval, Yader , Attia, Zachi I , Friedman, Paul A , Sandoval, Yader , Michieli, Laura De , Jaffe, Allan S.

Mayo Clinic

European Heart Journal. Acute Cardiovascular Care | December 20, 2022 | Volume: 12 | Issue: 2 | Pages: 106-114

10.1093/ehjacc/zuac156 | PMID 36537652 Get It

Abstract Aims Our goal was to evaluate a previously validated artificial intelligence–augmented electrocardiography (AI-ECG) screening tool for left ventricular systolic dysfunction (LVSD) in patients undergoing high-sensitivity-cardiac troponin T (hs-cTnT). Methods and results Retrospective application of AI-ECG for LVSD in emergency department (ED) patients undergoing hs-cTnT. AI-ECG scores (0–1) for probability of LVSD (left ventricular ejection fraction ≤ 35%) were obtained. An AI-ECG score ≥0.256 indicates a positive screen. The primary endpoint was a composite of post-discharge major adverse cardiovascular events (MACEs) at two years follow-up. Among 1977 patients, 248 (13%) had a positive AI-ECG. When compared with patients with a negative AI-ECG, those with a positive AI-ECG had a higher risk for MACE [48 vs. 21%, P &lt; 0.0001, adjusted hazard ratio (HR) 1.39, 95% confidence interval (CI) 1.11–1.75]. This was largely because of a higher rate of deaths (32 vs. 14%, P &lt; 0.0001; adjusted HR 1.26, 95% 0.95–1.66) and heart failure hospitalizations (26 vs. 6.1%, P &lt; 0.001; adjusted HR 1.75, 95% CI 1.25–2.45). Together, hs-cTnT and AI-ECG resulted in the following MACE rates and adjusted HRs: hs-cTnT &lt; 99th percentile and negative AI-ECG: 116/1176 (11%; reference), hs-cTnT &lt; 99th percentile and positive AI-ECG: 28/107 (26%; adjusted HR 1.54, 95% CI 1.01–2.36), hs-cTnT &gt; 99th percentile and negative AI-ECG: 233/553 (42%; adjusted HR 2.12, 95% CI 1.66, 2.70), and hs-cTnT &gt; 99th percentile and positive AI-ECG: 91/141 (65%; adjusted HR 2.83, 95% CI 2.06, 3.87). Conclusion Among ED patients evaluated with hs-cTnT, a positive AI-ECG for LVSD identifies patients at high risk for MACE. The conjoint use of hs-cTnT and AI-ECG facilitates risk stratification.
Unified Parkinson’s Disease Rating Scale (UPDRS) motor score subscale trajectories in Dementia with Lewy Bodies and Parkinson Disease Dementia in a community autopsy cohort
Adler, Charles, Shill, Holly A. , Mehta, Shyamal, Driver‐Dunckley, Erika, Choi, Alexander S., Belden, Christine M. , Goldfarb, Danielle, Beach, Thomas G. , Choudhury, Parichita , Zhang, Nan , Chen, Kewei , Shprecher, David , Mehta, Shyamal H. , Driver‐Dunckley, Erika , Choi, Alexander, Serrano, Geidy E. , Atri, Alireza

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S7 | Pages: No page available

10.1002/alz.066727 Get It

AbstractBackgroundWe previously reported that in our autopsy‐confirmed cohort of Dementia with Lewy Bodies (DLB), Parkinson’s Disease Dementia (PDD) and Alzheimer’s Disease (AD), DLB with parkinsonism (DLB+Park) predicted faster progression of UPDRS‐III scores compared to PDD, DLB without parkinsonism (DLB‐Park), and AD. This study examined annualized rate of change of UPDRS‐III subscales in our cohort.MethodsData included were from participants in Arizona Study of Aging and Neurodegenerative Diseases (AZSAND) with clinicopathologic diagnosis of DLB (n = 48), PDD (n = 98) or pure AD (n = 48), and longitudinal movement exams. Mixed effects model (accounting for age, education, and sex) was used to determine predicted mean UPDRS‐III and subscale scores (0‐4) for all groups. Individual UPDRS‐III subscale scores were derived for: Body Bradykinesia, Limb Bradykinesia, Gait, Postural Instability, Limb Rest Tremor, Neck Rigidity and Limb Rigidity. Where applicable, scores for multiple limbs involved were averaged.ResultsLongitudinal data was analyzed for over 1430‐participant years. Parkinsonism was present in 65.6% of DLB participants. PDD participants were more likely to be treated with dopaminergic agents (87.8%) compared to (p<0.001) DLB+Park (57.6%), DLB‐park (0%) and AD (2.1%). Frequency (29.4% vs. 29.0%) and severity (mean±SE = 0.4±0.07 and 0.4±0.12) of Limb Rest Tremor was similar for PDD and DLB+park. Limb Bradykinesia frequency and severity were PDD: 100%, 2.4±0.11, DLB+Park: 96.8%, 2.1±0.18, DLB‐Park: 20%, 0.4±0.23, and AD: 62%, 1.1±0.16. Frequency of gait abnormality was 98.5% in PDD, 90.3% in DLB+park, 60% in DLB‐Park and 57.8% in AD. Rigidity was most frequent in the PDD group (88.2%), followed by DLB+Park (71%), AD (19.6%), and none DLB‐park (0%). Over 8 years trajectories for limb bradykinesia and gait were greater for DLB+park than PDD (Figure 1, Cohen’s d range 0.89‐2.18 and 0.63‐1.99 over 8 years, p<0.001).ConclusionOur results suggest that DLB+Park group have faster motor progression predominantly related to gait abnormalities and limb bradykinesia. Future analyses will explore more convergent data, integrated effects of various measures and their differential contributions in this cohort.
Facial Nerve Schwannoma Treatment with Stereotactic Radiosurgery (SRS) versus Resection followed by SRS: Outcomes and a Management Protocol
Dayawansa, Sam , Mantziaris, Georgios , Mehta, Gautam U. , Leković, Gregory P. , Mathieu, David , Reda, Wael A. , Lee, Cheng-chia, Barnet, Gene, Lunsford, L. Dade , Sheehan, Jason P. , Mehta, Gautam U , Mathieu, David , Trifiletti, Daniel M , Mantziaris, Georgios , Dumot, Chloé , Kondziolka, Douglas , Reda, Wael A. , Liščák, Roman , Kaufmann, Anthony M. , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | December 1, 2022 | Volume: 85 | Issue: 01 | Pages: 075-080

10.1055/a-1990-2861 | PMID 38274481 Get It

Abstract Background Stereotactic radiosurgery (SRS) and resection are treatment options for patients with facial nerve schwannomas without mass effect. Objective This article evaluates outcomes of patients treated with SRS versus resection + SRS. Method We retrospectively compared 43 patients treated with SRS to 12 patients treated with resection + SRS. The primary study outcome was unfavorable combined endpoint, defined as worsening or new clinical symptoms, and/or tumor radiological progression. SRS (38.81 ± 5.3) and resection + SRS (67.14 ± 11.8) groups had similar clinical follow-ups. Results At the time of SRS, the tumor volumes of SRS (mean ± standard error; 1.83 ± 0.35 mL) and resection + SRS (2.51 ± 0.75 mL) groups were similar. SRS (12.15 ± 0.08 Gy) and resection + SRS (12.16 ± 0.14 Gy) groups received similar radiation doses. SRS group (42/43, 98%) had better local tumor control than the resection + SRS group (10/12, 83%, p = 0.04). Most of SRS (32/43, 74%) and resection + SRS (10/12, 83%) group patients reached a favorable combined endpoint following SRS (p = 0.52). Considering surgical associated side effects, only 2/10 patients of the resection + SRS group reached a favorable endpoint (p < 0.001).Patients of SRS group, who are > 34 years old (p = 0.02), have larger tumors (> 4 mL, 0.04), internal auditory canal (IAC) segment tumor involvement (p = 0.01) were more likely to reach an unfavorable endpoint. Resection + SRS group patients did not show such a difference. Conclusion While resection is still needed for larger tumors, SRS offers better clinical and radiological outcomes compared to resection followed by SRS for facial schwannomas. Younger age, smaller tumors, and non-IAC situated tumors are factors that portend a favorable outcome.
Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study
Ruan, Jia , Allen, Pamela B. , Cohen, Jonathon B. , Mehta-Shah, Neha, Lossos, Izidore S. , Flowers, Christopher R. , Larson, Melissa C. , Chen, Zhengming , Bennani, N. Nora , Jaye, David L. , Chihara, Dai , Vega, Francisco , Inghirami, Giorgio , Mou, Eric , Casulo, Carla , Mehta–Shah, Neha , Martin, Peter, Maurer, Matthew J. , Kahl, Brad S. , Cerhan, James R. , Feldman, Andrew L.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3666-3668

10.1182/blood-2022-164988 Get It

Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)
Krysiak, Kilannin, Trani, Lee , Gao, Feng , Geyer, Susan M. , Cashen, Amanda F. , Mehta-Shah, Neha, Lossos, Izidore S. , Leonard, John P. , Russler‐Germain, David A. , Ramirez, Cody A. , Mosior, Matthew , Watkins, Marcus P. , Gomez, Felicia , Skidmore, Zachary L. , Mehta–Shah, Neha , Kahl, Brad S. , Bartlett, Nancy L. , Hsi, Eric D. , Martin, Peter, Griffith, Malachi , Griffith, Obi L. , Fehniger, Todd A.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3543-3545

10.1182/blood-2022-157051 Get It

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristin
Friedberg, Jonathan W. , Thompson, Carrie A. , Zhang, Huilai , Thiéblemont, Catherine , Hu, Bei , Fonseca, Gustavo , Kim, Won-Seog, Campinha‐Bacote, Avrita, Yan, Mark, Hirata, Jamie , Sugidono, Matthew , Lee, Calvin , Sharman, Jeff P. , Trněný, Marek , Morschhauser, Franck , Salles, Gilles , Reagan, Patrick Michael , Hertzberg, Mark , Smolewski, Piotr , Martelli, Maurizio , Mehta, Amitkumar

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6623-6626

10.1182/blood-2022-157761 Get It